Don't forget, Senhance was ALF-X in Italy where it was CE marked in 2013. It has been on the market under one name or another for almost 8 years and has average sales of somewhere around two systems per year (including placements, leases... ). As for IP, ALF-X development began around 2002. Early patents may already be expiring. Trixie has an impressive IP portfolio by the numbers but how much of it is aging out rapidly?
It's not that Senhance can't do what it claims; it has received regulatory approvals on both sides of the Atlantic and who knows where else. The first issue is that floor space in an OR suite is at a premium. Hugo getting to the market should accelerate the Titan/Medtronic situation because as soon as Hugo hits the market, MDT will find the same issue regarding floor space. They will sell more than Trixie just because of the power of the Medtronic name, but it won't be the runaway sales phenomenon they are hoping for (all IMO, as always). The minimalist packaging and floor space requirements of Enos should prove much more popular once it gets to market, and aided by a substantially lower price tag, it should make a much bigger splash in the industry.
Mr. McNally has touted the SPORT and Enos systems as more affordable and hence more appropriate for target markets like smaller surgicenters, but I have a feeling hospitals, big and small, will be clamoring for the sleeker system, especially when price is also a consideration - which it always is.
So when MDT hits a brick wall with Hugo sales because it requires a large, dedicated OR room, they should quickly realize how badly they need Titan's offerings as their own. If, of course, they don't already own it outright by then. (Yes, still IMO. Feel free to offer a counterpoint!)
Message in reply to:
Yes, TRXC has regulatory approval but it is without question an inferior product/system compared to Titan's ENOS platform. With TRXC hitting a Billion dollar MC at one point, it is fair to say that a Single Port system like Tian with ANY REGULATORY APPROVAL would have a MC of $4-5B and a much higher BO value.
